Panacea Biotec and Apotex Inc. Settle Disputes with USD 5 Million Payment and Profit Share Modification

Panacea Biotec Ltd. and Apotex Inc. have executed a Settlement Agreement on July 09, 2025, recording full and final settlement of the disputes that were part of the arbitration proceedings. Apotex Inc. will pay USD 2.5 million within 30 days from the date of the Settlement Agreement and another USD 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) ('Paclitaxel'). The profit share for the supply by Panacea Biotec Pharma Limited (PBPL) of Paclitaxel for Canada and the USA will also be modified. This settlement will enhance profitability and funds availability in PBPL and the Company as a group.